Aldeyra Therapeutics Logo
US01438T1060
A111X8
ALDX

Aldeyra Therapeutics

Wczytywanie kursów wyceny...

Prognoza

Średnia cena docelowa analityków wynosi 8,81 € (+1298,41%). Mediana wynosi 9,11 € (+1346,03%).

Kupuj
  18
Trzymaj
  1
Sprzedaj
  0

Dyskusje w społeczności

Nie ma jeszcze dyskusji o tym aktywie.

Rozpocznij dyskusję

  • Aldeyra adds Darlene Deptula-Hicks to board of directors

    Aldeyra has appointed Darlene Deptula-Hicks to its board of directors; she brings more than 30 years of experience in the biotech sector and expertise as a finance executive at public and private life-science companies. Deptula-Hicks is currently interim CFO of Normunity and was previously CFO of F-star Therapeutics; her experience with IPOs, capital raising and M&A is expected to support potential commercialization of Aldeyra’s therapies. Aldeyra is developing RASP modulators and is advancing reproxalap and ADX-2191 in late-stage development; the company has a market capitalization of $104 million, a current ratio of 2.72, and its stock has traded well below last year’s level since the start of the year, while analyst price targets remain between $2 and $13. » Więcej na de.investing.com


  • Aldeyra Therapeutics repays $15 million loan and terminates credit facility

    Aldeyra Therapeutics repaid all outstanding liabilities of $15 million on April 1, thereby terminating the loan agreement with Hercules Capital in accordance with the contract. The company reports a balance sheet with more cash than debt and expects that cash, cash equivalents and marketable securities will fund operations through 2028. At the same time, Aldeyra faces regulatory pressure following an FDA Complete Response Letter for Reproxalap; analyst reactions are mixed (BTIG: buy, price target $9.00; H.C. Wainwright: neutral, price target $2.00). The stock trades well below last year’s level, reflecting the ongoing uncertainties. » Więcej na de.investing.com


  • Aldeyra Therapeutics: chief development officer Dr. Stephen G. Machatha to resign by March 2026

    Aldeyra Therapeutics announced that Dr. Stephen G. Machatha has voluntarily resigned as chief development officer; his last day will be no later than March 31, 2026. The company and Machatha reached a transition agreement under which he will remain employed through his departure, continue to receive his base salary and benefits, and have outstanding equity awards remain unchanged. As part of the agreement, Machatha will receive a one‑time payment of $88,000 and may receive an additional $88,000 if he signs further release agreements after leaving. The company emphasized that the resignation is not the result of any disagreement with management or the board. » Więcej na de.investing.com


  • Aldeyra receives EMA orphan drug status for ADX-2191 to treat rare retinal diseases

    Aldeyra Therapeutics has been granted orphan drug status by the European Medicines Agency for ADX-2191 for the treatment of inherited retinal dystrophies, including retinitis pigmentosa. The company will benefit from regulatory advantages and plans to conduct further clinical trials, while its financial position is described as solid. Additionally, progress has been reported in the development and approval applications of other medications. » Więcej na de.investing.com


  • Aldeyra receives positive FDA feedback for eye drug Reproxalap

    Aldeyra Therapeutics has announced that the US Food and Drug Administration (FDA) has accepted the resubmitted approval application for its eye drug Reproxalap, intended for the treatment of dry eye disease. The FDA's decision is expected by December 16, 2025, following the submission of additional clinical data. Analysts remain optimistic about the stock, and the company is financially well positioned to continue its development programs. » Więcej na de.investing.com

Dane finansowe spółki

W ostatnim kwartale Aldeyra Therapeutics osiągnęła przychody w wysokości 0 € i zysk netto w wysokości -3,32 mln €
(EUR) wrzesień 2026
YoY
Przychody 0 -
Zysk brutto 0 -
Zysk netto -3,32 mln 49,29%
EBITDA -3,19 mln 47,71%

Dane fundamentalne

Wskaźnik Wartość
Kapitalizacja rynkowa
38,23 mln €
Liczba akcji
60,36 mln
Maksimum/minimum z 52 tygodni
5,40 € - 0,48 €
Dywidendy Nie
Beta
1,29
C/Z (PE Ratio)
-2,18
PEG (PEG Ratio)
-0,02
C/WK (PB Ratio)
0,00
C/S (PS Ratio)
0,00

Profil spółki

Aldeyra Therapeutics, Inc., spółka biotechnologiczna, opracowuje i komercjalizuje leki na choroby oczu i choroby ogólnoustrojowe o podłożu immunologicznym. Wiodącym kandydatem na produkt spółki jest reproxalap, modulator reaktywnych gatunków aldehydów (RASP), który znajduje się w III fazie badań klinicznych w leczeniu zespołu suchego oka oraz alergicznego zapalenia spojówek. Spółka rozwija również ADX-629, doustnie podawany modulator RASP pierwszej klasy, który znajduje się w II fazie badań klinicznych w leczeniu łuszczycy, astmy i COVID-19; oraz ADX-2191, inhibitor reduktazy dihydrofolianowej, który znajduje się w fazie 3 w zapobieganiu proliferacyjnej witreoretinopatii oraz w fazie II badań klinicznych w leczeniu barwnikowego zwyrodnienia siatkówki, a także w leczeniu pierwotnego chłoniaka witreoretinalnego. Spółka ma umowę licencyjną z Madrigal Pharmaceuticals, Inc. dotyczącą opracowania ADX-1612, który hamuje białko chaperom w leczeniu chorób zapalnych. Spółka wcześniej działała pod nazwą Aldexa Therapeutics, Inc. i zmieniła nazwę na Aldeyra Therapeutics, Inc. w marcu 2014 roku. Aldeyra Therapeutics, Inc. została założona w 2004 roku i ma siedzibę w Lexington w stanie Massachusetts.

Nazwa
Aldeyra Therapeutics
CEO
Todd C. Brady
Siedziba Lexington, ma
Stany Zjednoczone
Strona internetowa
Sektor
Ochrona zdrowia
Branża
Biotechnologia
Debiut giełdowy
02.05.2014
Pracownicy 6

Symbole giełdowe

Giełda Symbol
NASDAQ
ALDX
Frankfurt
137.F
Düsseldorf
137.DU
München
137.MU
🍪

Parqet  używa plików cookie. Dowiedz się więcej